+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Paraoxonase-1 activity and pleiotropic properties of simvastatin in obese and non-obese patients with stable coronary artery disease (CAD)



Paraoxonase-1 activity and pleiotropic properties of simvastatin in obese and non-obese patients with stable coronary artery disease (CAD)



Przeglad Lekarski 73(2): 59-66



The study was aimed to assess paraoxonase-1 (PON1) activity, pleiotropic effects of simvastatin, and its relationship to Q192R and M55L polymorphisms in obese and non-obese subjects with stable coronary artery disease (CAD). The study included 53 subjects (22 obese) aged from 35 to 65 years with CAD. The control group consisted of 53 (18 obese) police officers without CAD. Patients with CAD were treated with simvastatin 40 mg/day for 12 months. The lipid profile, flow mediated dilation (FMD), intima media-thickness (IMT), fibrinogen, hs-CRP, TNF-α, urine 8-iso-PGF2α, and PON1 activity were evaluated in definite time points. PON1 polymorphisms were assessed at baseline in all observed individuals. The patients with CAD and obesity presented at baseline significantly increased hs-CRP level, insignificantly decreased FMD and lower PON1 activity compared to non-obese individuals. There was no association of obesity with 8-iso-PGF2α in the CAD and control group. The PON1 activity was significantly higher in 192R carriers in patients and controls, irrespective of obesity. Obesity was not associated with the effects of simvastatin on PON1 activity, urine 8-iso-PGF2α, and TNF-α, whereas it blunted its effect on the FMD improvement. The Q192R polymorphism was associated with simvastatin effectiveness on hs-CRP and FMD. Obesity and Q192R PON1 polymorphism are significantly associated with pleiotropic effects of simvastatin therapy in patients with stable CAD.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 058503195

Download citation: RISBibTeXText

PMID: 27197424


Related references

Tobacco smoking, paraoxonase-1 (PON1) activity and pleiotropic effects of simvastatin treatment in patients with stable coronary artery disease (CAD). Przeglad Lekarski 72(11): 597-605, 2016

Paraoxonase-1 and Simvastatin Treatment in Patients with Stable Coronary Artery Disease. International Journal of Vascular Medicine 2016: 6312478, 2016

Prevalence of diabetes mellitus among obese and non-obese patients with coronary artery disease. Journal of Ayub Medical College, Abbottabad 22(3): 64-67, 2012

Determination of risk factors in obese and non-obese patients with coronary artery disease. Acta Cardiologica 60(6): 625-629, 2006

Prevalence of hypertension among obese and non-obese patients with coronary artery disease. Journal of Ayub Medical College, Abbottabad 22(2): 130-133, 2011

Insulin secretion and sensitivity in non-obese and obese Japanese patients with coronary artery disease. Metabolism Clinical & Experimental 51(2): 184-188, 2002

Coronary flow velocity reserve by echocardiography: feasibility, reproducibility and agreement with PET in overweight and obese patients with stable and revascularized coronary artery disease. Cardiovascular Ultrasound 14(1): 22, 2017

Low paraoxonase 1 arylesterase activity and high von Willebrand factor levels are associated with severe coronary atherosclerosis in patients with non-diabetic stable coronary artery disease. Medical Science Monitor 20: 2421-2429, 2015

Serum Levels of Visfatin and Interleukin-6 in Non-Obese Versus Obese Men with Coronary Artery Disease. Journal of the College of Physicians and Surgeons--Pakistan 27(2): 71-74, 2017

Effect of liraglutide on estimates of lipolysis and lipid oxidation in obese patients with stable coronary artery disease and newly diagnosed type 2 diabetes: A randomized trial. Diabetes, Obesity and Metabolism 2019, 2019

Comparing the effects of a cardiac rehabilitation program on functional capacity of obese and non-obese women with coronary artery disease. Arya Atherosclerosis 8(2): 55-58, 2012

Paraoxonase, arylesterase and lactonase activities of paraoxonase-1 (PON1) in obese and severely obese women. Scandinavian Journal of Clinical and Laboratory Investigation 78(1-2): 18-24, 2017

Obese sedentary patients with dyspnoea on exertion who are at low risk for coronary artery disease by clinical criteria have a very low prevalence of coronary artery disease. Clinical Obesity 4(3): 143-149, 2015

The role of central fat distribution in coronary artery disease in obesity: comparison of nondiabetic obese, diabetic obese, and normal weight subjects. International Journal of Obesity and Related Metabolic Disorders 23(11): 1129-1135, 1999

Comparison of pre- and postoperative pulmonary function in obese and non-obese female patients undergoing coronary artery bypass graft surgery. Respirology 11(6): 761-766, 2006